Business Context and Reporting Period
This Form 6-K filing by Oculis Holding AG, dated August 1, 2025, reports on a material corporate event occurring in July 2025. The registrant, a Swiss-based company, entered into an amended and restated loan facility agreement with Kreos Capital VII (UK) Limited, a fund managed by BlackRock, Inc.
Key Financial Metrics and Debt Structure
The filing details a significant restructuring of the company's debt capacity rather than reporting standard operating financials such as revenue or cash flow for the period.
- Total Borrowing Capacity: The facility provides up to the EUR equivalent of CHF 75.0 million, with an option to increase to CHF 100.0 million.
- Tranche Structure: The loan comprises three tranches (Loans 1, 2, and 3) of CHF 25.0 million each, plus an additional potential tranche of CHF 25.0 million subject to mutual agreement.
- Interest Rates: Fixed rates (cash and PIK) of 9.7% for Loan 1, 9.6% for Loan 2, and 9.5% for Loan 3.
- Drawdown Conditions: Availability is conditional on the registrant maintaining a debt-to-market cap ratio of 15% or less at the time of each drawdown.
- Transaction Fees: A restatement fee of approximately CHF 500,000 was paid. Additional transaction fees of approximately CHF 562,500 are payable upon future drawdowns. An end-of-loan fee of 4.5% of drawn amounts applies upon full repayment.
Material Changes Versus Prior Period
The Amended Loan Agreement replaces the prior loan agreement dated May 29, 2024. Key changes include:
- Upsized Facility: The borrowing capacity has been increased from the prior agreement to the current CHF 75.0 million (potentially CHF 100.0 million).
- Warrant Amendment: An amended warrant was issued to an affiliate of the lender for up to 494,259 ordinary shares. The exercise price is $12.17 for 361,011 shares (from the prior agreement) and $18.64 for the remaining 133,248 shares (reflecting the upsized facility).
- Current Status: No amount was drawn at the signing of the agreement on July 31, 2025.
Outlook, Risks, and Management Commentary
Management intends to use proceeds from the facility for general corporate purposes. The filing highlights several risks and contingencies:
- Maturity Dates: Loans 1, 2, and 3 generally expire on December 31, 2029. However, if certain conditions are not met, the interest-only periods for Loans 1 and 2 shorten to December 31, 2026, and these loans would mature on June 30, 2029.
- Mandatory Prepayment: The loan is subject to mandatory prepayment in the event of a change of control or specified asset dispositions.
- Covenants: The agreement includes customary affirmative and negative covenants.
- Warrant Vesting: The warrant is exercisable for 59,310 shares as of the signing date, with additional shares vesting ratably based on future loan drawdowns.
Investor Verification Checklist
- Verify the company's current market capitalization to assess the feasibility of the 15% debt-to-market cap drawdown condition.
- Monitor the specific development milestones that could shorten the interest-only period for Loans 1 and 2 to December 31, 2026.
- Review the full text of the Amended Loan Agreement and Amended Warrant, expected to be filed with the 2025 Form 20-F, for complete covenant details.
- Track the actual drawdown amounts to determine the total dilution impact from the warrant exercise.